Impact of Continuing Medical Education (CME) Insulin Program - Full Text View

Sponsors and Collaborators:	Park Nicollet Institute International Diabetes Center Eli Lilly and Company Novo Nordisk United Health Care Merck
Information provided by:	Park Nicollet Institute
ClinicalTrials.gov Identifier:	NCT00824603

Purpose

The purpose of this study is to determine if a continuing medical education (CME) program can change primary care providers' use of insulin therapy - their confidence in selecting doses and engagement of patients in the decision making as to whether to initiate insulin therapy.

Condition
Diabetes

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes

Further study details as provided by Park Nicollet Institute:

Primary Outcome Measures:

We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. [ Time Frame: pre program survey & 2-4 month post program survey ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

pre-CME training level of patient's A1c when starting insulin therapy compared to post-CME training level of patient's A1c when starting insulin therapy [ Time Frame: pre program survey and 2-4 month post program survey ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	300
Study Start Date:	June 2006
Estimated Study Completion Date:	June 2010

Groups/Cohorts
primary care provider attending insulin CME Training

Detailed Description:

We will determine whether attendees' self-reported confidence and use of insulin with persons with type 2 diabetes changes after they attend the CME program. Specifically, we will address the following questions:

Question 1. Clinical guidelines. Is insulin initiated earlier (at a lower A1C)?

Question 2. Decision-making. Does confidence in selecting a starting insulin regimen change? Does confidence in selecting a starting insulin dose change? Does confidence in adjusting insulin change? Does confidence in discussion nutrition guidelines change?

Question 3. Application. Do more patients start using insulin? Who usually selects starting dose? How is starting dose selected? How often is insulin adjusted?

Question 4. Resources. How available are protocols for insulin use? How available is adequate time to monitor insulin therapy? How available is staff to teach insulin injections? How available is staff to help adjust insulin?

Eligibility

Ages Eligible for Study:	25 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Primary care providers affiliated with the participating healthcare organizations were invited to attend.

Criteria

Inclusion Criteria:

primary care provider attending CME training

Exclusion Criteria:

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00824603

Locations

United States, Minnesota
International Diabetes Center
Minneapolis, Minnesota, United States, 55416

Sponsors and Collaborators

Park Nicollet Institute

International Diabetes Center

Eli Lilly and Company

Novo Nordisk

United Health Care

Merck

Investigators

Principal Investigator:

Margaret Powers, PhD

International Diabetes Center

More Information

No publications provided

Responsible Party:	International Diabetes Center ( Margaret Powers, PhD )
Study ID Numbers:	03425-06-C
Study First Received:	January 15, 2009
Last Updated:	January 16, 2009
ClinicalTrials.gov Identifier:	NCT00824603 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Diabetes Mellitus, Type 2
Diabetes Mellitus
Insulin

ClinicalTrials.gov processed this record on May 07, 2009